

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

POSTPONEMENT OF BOARD MEETING

Reference is made to the notice of CanSino Biologics Inc. (the “**Company**”) dated August 16, 2023 in relation to a meeting of the board (the “**Board**”) of directors (the “**Directors**”) of the Company to be held on Monday, August 28, 2023 for the purpose of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2023 (the “**2023 Interim Results**”) and its publication.

The Board hereby announces that the date of the Board meeting for approving the 2023 Interim Results and its publication, will be postponed to Wednesday, August 30, 2023.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 28, 2023

As of the date of this notice, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.